Bottom Line: When commercial success is not mirrored in the federal landscape, closing the adoption gap requires a pivot from commercial tactics to a strategy of institutional integration. The strategic miscalculation among pharmaceutical and medical device manufacturers is one of institutional translation. By classifying the VA and DoD as merely large Integrated Delivery Networks (IDNs), commercial leadership teams wrongly assume federal systems obey commercial mechanics. The fundamental...

Bottom Line: In a rapidly evolving federal healthcare environment, manufacturer success in 2026 hinges on an organization’s ability to execute against five critical catalysts that are currently reshaping the market landscape. The federal healthcare landscape - encompassing the Department of Veterans Affairs (VA) and the Department of Defense (DoD) - is entering a period of significant structural transition. Several regulatory and administrative events will change how manufacturers access this...

Bottom Line: To transform federal participation into a structured component of portfolio value, manufacturers must build an integrated strategy that links market access to disciplined pricing governance, effectively balancing the FSS's role as both an access key for stable volume and a pricing governor that mandates value control. For manufacturers selling into the direct purchase federal healthcare market, particularly, the Veterans Health Administration (VHA) and Defense Health Agency...